Total Payments
$1,156
2023 Payments
$38.20
Companies
18
Transactions
81
Medicare Patients
1,638
Medicare Billing
$187,933
Payment Breakdown by Category
Food & Beverage$1,144 (98.9%)
Education$12.29 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,144 | 80 | 98.9% |
| Education | $12.29 | 1 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $174.95 | 14 | $0 (2020) |
| PFIZER INC. | $147.11 | 12 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $139.66 | 9 | $0 (2020) |
| Celgene Corporation | $110.49 | 6 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $100.64 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $84.64 | 6 | $0 (2020) |
| Daiichi Sankyo Inc. | $71.55 | 4 | $0 (2019) |
| Genentech USA, Inc. | $61.48 | 5 | $0 (2018) |
| Janssen Biotech, Inc. | $54.82 | 4 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $51.31 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $38.20 | 2 | AstraZeneca Pharmaceuticals LP ($24.98) |
| 2022 | $33.42 | 2 | Medtronic, Inc. ($17.02) |
| 2021 | $11.13 | 1 | Medtronic, Inc. ($11.13) |
| 2020 | $87.18 | 6 | Lilly USA, LLC ($24.02) |
| 2019 | $445.07 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($115.49) |
| 2018 | $278.81 | 21 | Takeda Pharmaceuticals U.S.A., Inc. ($42.37) |
| 2017 | $262.60 | 19 | PFIZER INC. ($73.60) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/26/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 03/02/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Oncology | ||||||
| 12/13/2022 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 04/28/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | Medtronic, Inc. | OSTEOCOOL RF ABLATION (Device) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 03/24/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Oncology | ||||||
| 03/10/2020 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $16.00 | General |
| 02/04/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug), Nubeqa | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: Oncology | ||||||
| 01/22/2020 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Oncology | ||||||
| 12/31/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Oncology | ||||||
| 12/17/2019 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug), Aliqopa | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Oncology | ||||||
| 11/12/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $13.83 | General |
| 10/29/2019 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug), Aliqopa | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Oncology | ||||||
| 10/23/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Oncology | ||||||
| 10/08/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Oncology | ||||||
| 09/17/2019 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: Anemia | ||||||
| 09/10/2019 | Bayer HealthCare Pharmaceuticals Inc. | Aliqopa (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Oncology | ||||||
| 09/03/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Oncology | ||||||
| 08/20/2019 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Hematology / Oncology | ||||||
| 07/30/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Oncology | ||||||
| 07/23/2019 | Bayer HealthCare Pharmaceuticals Inc. | Aliqopa (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 427 | 775 | $245,846 | $60,862 |
| 2022 | 8 | 354 | 519 | $124,059 | $39,946 |
| 2021 | 7 | 401 | 537 | $127,797 | $38,170 |
| 2020 | 7 | 456 | 851 | $251,767 | $48,955 |
Total Patients
1,638
Total Services
2,682
Medicare Billing
$187,933
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 196 | $76,407 | $20,512 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 234 | $62,319 | $15,941 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $35,225 | $6,922 | 19.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 51 | 56 | $21,728 | $5,214 | 24.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 86 | $17,802 | $4,776 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 79 | $13,371 | $3,586 | 26.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 28 | $16,016 | $3,449 | 21.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 18 | $2,978 | $463.21 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 206 | $36,874 | $14,570 | 39.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 73 | 73 | $25,689 | $7,112 | 27.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $20,020 | $5,146 | 25.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 37 | 37 | $14,356 | $3,755 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 34 | $9,897 | $3,620 | 36.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 34 | 62 | $12,834 | $3,182 | 24.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 46 | $3,635 | $1,990 | 54.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 24 | 26 | $754.00 | $571.52 | 75.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 102 | 166 | $37,113 | $10,426 | 28.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 66 | $11,814 | $5,149 | 43.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 47 | 47 | $16,450 | $5,020 | 30.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 35 | 40 | $13,200 | $4,263 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 94 | 106 | $16,006 | $4,043 | 25.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $9,730 | $2,505 | 25.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 43 | $8,865 | $2,444 | 27.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 21 | $8,149 | $2,241 | 27.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $5,406 | $1,331 | 24.6% |
About Dr. Michael Batalo, M.D
Dr. Michael Batalo, M.D is a Hematology & Oncology healthcare provider based in Midlothian, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/21/2009. The National Provider Identifier (NPI) number assigned to this provider is 1750525838.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Batalo, M.D has received a total of $1,156 in payments from pharmaceutical and medical device companies, with $38.20 received in 2023. These payments were reported across 81 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,144).
As a Medicare-enrolled provider, Batalo has provided services to 1,638 Medicare beneficiaries, totaling 2,682 services with total Medicare billing of $187,933. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Midlothian, VA
- Active Since 04/21/2009
- Last Updated 11/06/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750525838
Products in Payments
- Vitrakvi (Drug) $92.85
- CYRAMZA (Drug) $83.70
- ALIMTA (Drug) $77.66
- TAGRISSO (Drug) $75.66
- INJECTAFER (Drug) $71.55
- NINLARO (Drug) $65.40
- IBRANCE (Drug) $60.08
- Revlimid (Drug) $57.23
- KEYTRUDA (Biological) $49.72
- Aliqopa (Drug) $46.81
- DARZALEX (Biological) $42.03
- Abraxane (Drug) $36.20
- XALKORI (Drug) $35.49
- OPDIVO (Biological) $35.42
- Avastin (Biological) $34.94
- Alecensa (Biological) $26.54
- CALQUENCE (Drug) $24.98
- INLYTA (Drug) $24.14
- OSTEOCOOL RF ABLATION SYSTEM (Device) $17.02
- PIQRAY (Drug) $16.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.